In its fourth quarter 2024 investor letter, Brown Advisors Global Leaders Strategy emphasized stocks such as Illumina, Inc. (NASDAQ:ILMN). Illumina, Inc. (NASDAQ:ILMN) offers sequencing- and array ...

Washing your car involves tackling the grime with a quality selection of cleaning products, one of which should be the best pre-wash. This miracle chemical is designed to tackle the worst offending ...

It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The NextSeq 550 has been in use since 2018 and is great for mid-range projects such as ...

The Genomics Core offers a wide range of genomic and DNA/RNA services. We operate the Illumina NovaSeq X Plus, NextSeq 550, and MiSeq platforms for all Next Generation Sequencing and offer an ...

Illumina is raising the curtain on its upcoming ... The company said its spatial technology will run on its current NextSeq and NovaSeq hardware through a new multimodal software platform, with ...

The spatial solution surpasses industry standards for scale and accuracy, and is compatible with Illumina NextSeq and NovaSeq sequencers, thereby materially reducing the cost of running large-scale ...

Users will go through a chemistry workflow to permeabilize, hybridize, and make a cDNA library that will be fully compatible with illumina sequencers—both NovaSeq and NextSeq. Users can also ...

Follow us on Facebook and join our Telegram channel for the latest updates. Prime Minister and Finance Minister Lawrence Wong mentioned Illumina, the Nasdaq-listed biotechnology firm headquartered in ...

For the first time, China has put American genome-sequencing equipment manufacturer Illumina on its “unreliable entity list”. The move was a direct counter to the US imposing sanctions on Beijing ...

Traditional solid phase extraction (SPE) revolutionized sample preparation, but it often involves high solvent consumption and complex procedures. Micro solid phase extraction (μSPE) offers a ...

Illumina reported Q3 2024 revenue of $1.08 billion -- in line with analysts' consensus estimate. Non-GAAP EPS was $1.14, exceeding the $0.879 consensus and indicating strong cost control. Despite ...